Fax: (011) 81-29-853-3169
Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival
Version of Record online: 17 JUN 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 15, pages 3437–3445, 1 August 2009
How to Cite
Akaza, H., Hinotsu, S., Usami, M., Arai, Y., Kanetake, H., Naito, S. and Hirao, Y. (2009), Combined androgen blockade with bicalutamide for advanced prostate cancer. Cancer, 115: 3437–3445. doi: 10.1002/cncr.24395
We thank the patients and their families for their participation in this study. We also thank the physicians and support staff in each institute and Dr. Sharon Gladwin from Complete Medical Communications, who provided medical writing support.
Institutions participating in the study: Hokkaido University Hospital, Sapporo Medical University Hospital, Hirosaki University School of Medicine and Hospital, Tohoku University Hospital, Yamagata University Hospital, Tsukuba University Hospital, Teikyo University Chiba Medical Center, Asahi Hospital, Nihon University Itabashi Hospital, Toranomon Hospital, Keio University Hospital, Showa University Hospital, the University of Tokyo Hospital, the Jikei University School of Medicine, Tokyo Medical University Hospital, Tokyo Women's Medical University Hospital, Yokohama City University Hospital, Kitasato University Hospital, Fujieda Municipal General Hospital, Niigata University Medical and Dental Hospital, Niigata Cancer Center Hospital, Kanazawa University Hospital, Nagoya Daini Red Cross Hospital, Nagoya City University Hospital, Gifu University Hospital, University Hospital Kyoto Prefectural University of Medicine, Kyoto University Hospital, Nara Medical University Hospital, Osaka University Hospital, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka City University Hospital, Kansai Medical University Takii Hospital, Kobe University Hospital, Nishi-Kobe Medical Center, Okayama University Hospital, Kawasaki Medical School Hospital, Kurashiki Central Hospital, Hiroshima University Hospital, Shimane University Hospital, Tokushima University Hospital, Shikoku Cancer Center, Kochi Medical School Hospital, Kyushu University Hospital, Harasanshin Hospital, Nagasaki University Hospital of Medicine and Dentistry, Sasebo General Hospital, and Nagasaki Medical Center.
See also on pages 3376-8.
- Issue online: 20 JUL 2009
- Version of Record online: 17 JUN 2009
- Manuscript Accepted: 19 NOV 2008
- Manuscript Revised: 14 NOV 2008
- Manuscript Received: 8 SEP 2008
- 8Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol. 2004; 34: 20-28., , , et al.
- 9Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis. 2007; 10: 194-201., , , et al.
- 12Japanese Urological Association and the Japanese Society of Pathology. General rule for clinical and pathological studies on prostatic cancer. 2nd edition. Tokyo: Kanehara. 1992.
- 14Preliminary trial for clinical phase III study of Casodex-combination therapy with LH-RH agonist for prostate cancer. J N Remed Clin. 1999; 48: 1512-1533., , .
- 21Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol. 2008; 134: 1385-1396., , , et al.
- 22[Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer]. Gan To Kagaku Ryoho. 2007; 34: 589-595., , , et al.